Oddo BHF raises target for Sartorius Stedim stock to EUR 281
Published on 10/05/2026 at 13:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sartorius Stedim Biotech (ISIN FR0013154002) has a new analyst valuation anchor: Oddo BHF raised its price target from EUR 239 to EUR 281 on October 2, 2026, while maintaining an outperform rating, according to Ideal Investisseur. The target is 33.75 percent above the EUR 210.10 Lang & Schwarz price on October 5, 2026.
Analysts lift the valuation bar
The Oddo BHF move followed Goldman Sachs raising its target from EUR 208 to EUR 223 on October 1, 2026, while retaining a Buy rating, according to finanzen.at. The two target revisions point to a market debate centered on the recovery in bioprocessing demand rather than on a new corporate transaction.
That valuation case is built against a recent operating update. Sartorius Stedim reported EUR 1.53 billion in revenue, EUR 463.70 million in EBITDA and a 31.40 percent EBITDA margin for the first half of 2026, according to the company's investor-relations page.
First-half results set the benchmark
The first-half revenue figure gives investors a concrete scale for the full-year outlook. Sartorius Stedim's 2026 guidance calls for revenue of EUR 3.15 billion and EBITDA of EUR 989.20 million, while the first-half EBITDA margin was 31.40 percent, according to Sartorius Stedim Biotech. The comparison matters because the new analyst targets assume that improving demand can translate into sustained profitability.
The next scheduled reporting point is October 22, 2026, when Sartorius Stedim is expected to publish its third-quarter results, according to Boursorama. That date gives the market a near-term test for whether the first-half recovery is continuing into the second half.
Stock remains below its yearly high
The stock's EUR 210.10 Lang & Schwarz price is 6.21 percent below the EUR 224.00 52-week high and EUR 60.10 above the EUR 150.00 52-week low, based on October 5, 2026 market data. Market capitalization was EUR 20.4 billion on the same date.
Sartorius Stedim Biotech was trading at EUR 210.10 at Lang & Schwarz on October 5, 2026 at 1:37 p.m. CEST, up 0.24 percent versus the prior close of EUR 209.60 on October 2, 2026. The further course of trading is shown by the continuously updated real-time quote of Sartorius Stedim stock.
Sartorius Stedim Biotech stock facts
- Company: Sartorius Stedim Biotech S.A.
- ISIN: FR0013154002
- Ticker: DIM
- Primary exchange: Euronext Paris
- Price Lang & Schwarz as of October 5, 2026, 1:37 p.m. CEST: EUR 210.10
- Change versus prior close: plus 0.24 percent
- Prior close Lang & Schwarz (October 2, 2026): EUR 209.60
- Market capitalization: EUR 20.4 billion (as of October 5, 2026)
- 52-week range: EUR 150.00-EUR 224.00 (as of October 5, 2026)
- Sector / Industry: Healthcare / Medical Instruments and Supplies
- Index membership: SBF 120
- Next earnings date: October 22, 2026
